ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2022 and some content may be unavailable. To unlock all content for 2022, please visit the archives.

Abstract: SA-PO462

Metabolites Associated With Uremic Symptoms in Hemodialysis Patients

Session Information

Category: Dialysis

  • 701 Dialysis: Hemodialysis and Frequent Dialysis

Authors

  • Myint, Leslie, Macalaster College, St. Paul, Minnesota, United States
  • Rhee, Eugene P., Massachusetts General Hospital, Boston, Massachusetts, United States
  • Wulczyn, Kendra E., Massachusetts General Hospital, Boston, Massachusetts, United States
  • Kalim, Sahir, Massachusetts General Hospital, Boston, Massachusetts, United States
  • Segev, Dorry L., NYU Langone Health, New York, New York, United States
  • McAdams-DeMarco, Mara, NYU Langone Health, New York, New York, United States
  • Thadhani, Ravi I., Massachusetts General Hospital, Boston, Massachusetts, United States
  • Moe, Sharon M., Indiana University School of Medicine, Indianapolis, Indiana, United States
  • Moorthi, Ranjani N., Indiana University School of Medicine, Indianapolis, Indiana, United States
  • Hostetter, Thomas H., University of North Carolina System, Chapel Hill, North Carolina, United States
  • Himmelfarb, Jonathan, University of Washington School of Medicine, Seattle, Washington, United States
  • Meyer, Timothy W., Stanford University School of Medicine, Stanford, California, United States
  • Powe, Neil R., University of California San Francisco, San Francisco, California, United States
  • Tonelli, Marcello, University of Calgary, Calgary, Alberta, Canada
  • Shafi, Tariq, University of Mississippi Medical Center, Jackson, Mississippi, United States
Background

The specific substances causing uremic symptoms are unknown. We used untargeted metabolomics to identify metabolite markers associated with uremic symptoms in hemodialysis patients.

Methods

We profiled 29,591 plasma metabolites (Broad Institute) in 517 Longitudinal US/Canada Incident Dialysis (LUCID) study participants at baseline (discovery) and subset at year 1 (validation). We concurrently assessed uremic symptoms (KDQOL-36; fatigue, pruritus, anorexia, nausea/vomiting, daytime sleepiness, difficulty concentrating, and pain) and investigated demographic- and clinical covariate-adjusted associations using: a) metabolite-wise linear models with empirical Bayesian inference, accounting for multiple testing; b) LASSO; c) random forest (RF) models. We defined robust symptom-metabolite associations if significant in linear models and at least medium importance in both LASSO and RF models.

Results

The mean age was 61 years, 80% were male, and mean duration from dialysis initiation was 62 days. We identified several metabolites robustly associated with uremic symptoms; 3 metabolites associated with anorexia, 8 with pruritus, and 1 each with pain, sleepiness, and concentration (Table). Higher levels of 2-hydroxy-3-methylpentanoate/hydroxyisocaproate were linked to higher severity of anorexia, bodily pain, and difficulty concentrating. Lower levels of indoxyl sulfate were associated with higher severity of daytime sleepiness. No metabolites were significantly associated with fatigue or nausea/vomiting.

Conclusion

We identified several metabolites associated with uremic symptoms, which could be targeted for future interventions if replicated in other studies.

Funding

  • Other NIH Support